Vericel (VCEL) Leases (2019 - 2026)
Vericel recorded quarterly Leases of $686000.0 in Q1 2026, down 98.94% quarter-over-quarter from $64.8 million in Q4 2025, and down 99.0% year-over-year from $68.7 million in Q1 2025.
Vericel's Leases history runs 8 years deep, the most recent figure standing at $686000.0 for Q1 2026.
- In Q1 2026, Leases fell 99.0% year-over-year to $686000.0; the TTM figure through Mar 2026 stood at $686000.0 (down 99.0% YoY), while the FY2025 annual figure was $64.8 million, up 9342.27% from the prior year.
- Leases came in at $686000.0 for Q1 2026 at Vericel, down from $64.8 million in the prior quarter.
- In the past five years, Leases ranged from a high of $75.1 million in Q2 2023 to a low of $37000.0 in Q4 2022.
- A 5-year average of $43.7 million and a median of $44.7 million in 2022 frame the typical range for Leases.
- Across the five-year window, Leases slumped 99.92% in 2022 and soared 198445.95% in 2023, its largest moves.
- Vericel's Leases stood at $37000.0 in 2022, then jumped by 198445.95% to $73.5 million in 2023, then tumbled by 99.07% to $686000.0 in 2024, then jumped by 9342.27% to $64.8 million in 2025, then slumped by 98.94% to $686000.0 in 2026.
- According to Business Quant data, Leases over the past three periods registered $686000.0, $64.8 million, and $66.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 61,822.50 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 189.30 Mn |
| 10 | Vericel | 1.69 Bn | 1.55 Bn | 49.27 Mn | 686,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 686,000.00 |
| Dec 31, 2025 | 64.77 Mn |
| Sep 30, 2025 | 66.09 Mn |
| Jun 30, 2025 | 67.40 Mn |
| Mar 31, 2025 | 68.72 Mn |
| Dec 31, 2024 | 686,000.00 |
| Sep 30, 2024 | 3.60 Mn |
| Jun 30, 2024 | 3.00 Mn |
| Mar 31, 2024 | 73.68 Mn |
| Dec 31, 2023 | 73.46 Mn |
| Sep 30, 2023 | 73.29 Mn |
| Jun 30, 2023 | 75.06 Mn |
| Mar 31, 2023 | 40.85 Mn |
| Dec 31, 2022 | 37,000.00 |
| Sep 30, 2022 | 42.63 Mn |
| Jun 30, 2022 | 43.58 Mn |
| Mar 31, 2022 | 44.65 Mn |
| Dec 31, 2021 | 45.72 Mn |
| Sep 30, 2021 | 46.71 Mn |
| Jun 30, 2021 | 47.80 Mn |
| Mar 31, 2021 | 102,000.00 |
| Dec 31, 2020 | 50.11 Mn |
| Sep 30, 2020 | 120,000.00 |
| Jun 30, 2020 | 129,000.00 |
| Mar 31, 2020 | 24.50 Mn |
| Dec 31, 2019 | 25.10 Mn |
| Sep 30, 2019 | 25.62 Mn |
| Jun 30, 2019 | 24.82 Mn |
| Mar 31, 2019 | 25.18 Mn |